View in EDS PDF Full Text

Ahorros para el sistema de salud colombiano con la financiación externa de estudios clínicos oncológicos.

Saved in:
Bibliographic Details
Title: Ahorros para el sistema de salud colombiano con la financiación externa de estudios clínicos oncológicos.
Alternate Title: Savings to the Colombian health system with the implementation of externally funded oncology clinical trials.
Authors: Aruachan, Sandra1, González, Manuel2, Rojas, Danis M.1, Ospina, Javier1, Duque-Varela, Santiago3, Ángel Castaño, Andrés3
Source: Biomédica: Revista del Instituto Nacional de Salud. Mar2025, Vol. 45 Issue 1, p51-63. 13p.
Subjects: RANDOMIZED controlled trials, CLINICAL trials, MIDDLE-income countries, ANTINEOPLASTIC agents, MEDICAL research
Abstract (English): Introduction. Spending on drugs to treat cancer will increase by 9-12% annually until 2025. For health systems in high and middle-income countries -such as Colombia- and with an increasing trend of new cancer cases, clinical research can contribute to the efficient use of the system resources available without undermining the timeliness and quality of healthcare. Objective. To calculate the savings generated to the Colombian health system by the implementation of externally funded clinical trials for cancer. Materials and methods. We conducted an observational, longitudinal, descriptive, and retrospective study analyzing participant's medical records of clinical trials between 2016 and 2022 at the Clínica IMAT Oncomédica Auna, Colombia. Results. The total savings to the health system for external financing of oncology drugs was USD $1,526,320, and the monthly weighted average savings per patient was USD $3,257. The participation of breast cancer patients in randomized controlled clinical trials (n = 138) accounted for 24% (USD $369,363) of the total savings. Participants with clinical stage IV and III accounted for 41.7% (USD $636,475) and 31.06% (USD $473,159), respectively, of the total savings to the general social security health system in Colombia from external financing of oncological drugs. Conclusion. The participation of cancer patients in clinical trials mitigated costs to the Colombian health system, especially in women with breast cancer and in those patients with clinical stage IV of the disease. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introducción. El gasto en medicamentos para tratar el cáncer aumentará entre el 9 y el 12 % anual hasta el 2025. Para los sistemas de salud de los países con un ingreso medio-alto, como Colombia, y con una tendencia creciente de nuevos casos de cáncer, la investigación clínica puede contribuir al uso eficiente de los recursos que tiene el sistema sin menoscabar la oportunidad y la calidad de la atención. Objetivo. Calcular el ahorro generado al sistema de salud colombiano por la implementación de estudios clínicos para cáncer con financiación externa. Materiales y métodos. Se desarrolló un estudio observacional, longitudinal, descriptivo y retrospectivo, basado en el análisis de las historias clínicas de participantes de estudios clínicos realizados entre el 2016 y el 2022 en la Clínica IMAT Oncomédica Auna, Colombia. Resultados. El ahorro en medicamentos oncológicos para el sistema de salud por financiación externa fue de USD $1'526.320 y el ahorro promedio ponderado mensual por paciente fue de USD $3.257. La participación de los pacientes con cáncer de mama en los estudios clínicos controlados aleatorizados (n = 138) representó el 24 % (USD $369.363) del total de los ahorros. La financiación externa de medicamentos oncológicos para los participantes con cáncer en estadio clínico IV y III, representó el 41,7 % (USD $636.475) y el 31,06 % (USD $473.159), respectivamente, del ahorro total para el Sistema General de Seguridad Social en Salud de Colombia. Conclusión. La participación de los pacientes con cáncer en los estudios clínicos evitó costos al sistema de salud de Colombia. El ahorro fue mayor en las mujeres con cáncer de mama y en aquellos pacientes con cáncer en estadio clínico IV. [ABSTRACT FROM AUTHOR]
Copyright of Biomédica: Revista del Instituto Nacional de Salud is the property of Instituto Nacional de Salud of Colombia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:Introduction. Spending on drugs to treat cancer will increase by 9-12% annually until 2025. For health systems in high and middle-income countries -such as Colombia- and with an increasing trend of new cancer cases, clinical research can contribute to the efficient use of the system resources available without undermining the timeliness and quality of healthcare. Objective. To calculate the savings generated to the Colombian health system by the implementation of externally funded clinical trials for cancer. Materials and methods. We conducted an observational, longitudinal, descriptive, and retrospective study analyzing participant's medical records of clinical trials between 2016 and 2022 at the Clínica IMAT Oncomédica Auna, Colombia. Results. The total savings to the health system for external financing of oncology drugs was USD $1,526,320, and the monthly weighted average savings per patient was USD $3,257. The participation of breast cancer patients in randomized controlled clinical trials (n = 138) accounted for 24% (USD $369,363) of the total savings. Participants with clinical stage IV and III accounted for 41.7% (USD $636,475) and 31.06% (USD $473,159), respectively, of the total savings to the general social security health system in Colombia from external financing of oncological drugs. Conclusion. The participation of cancer patients in clinical trials mitigated costs to the Colombian health system, especially in women with breast cancer and in those patients with clinical stage IV of the disease. [ABSTRACT FROM AUTHOR]
ISSN:01204157
DOI:10.7705/biomedica.7239